Post-Esmo Wrap with Leerink Partners & Truist Securities: BI Replay

How has the cancer treatment landscape evolved following the 50th ESMO Congress in Berlin? Join Sam Fazeli, Director of Research, Global Industries and Senior Pharmaceuticals Analyst at Bloomberg Intelligence, Andrew Berens M.D., Senior Managing Director, Targeted Oncology, Daina Graybosch, Ph.D., Senior Managing Director, Immuno-Oncology and Jonathan Chang, Ph.D., CFA, Senior Managing Director, Emerging Oncology at Leerink Partners for a discussion breaking down key datasets, commercial implications, and how the latest developments could change clinical practice.